Daniel Collins
Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.
More From Daniel Collins
Teva Pharmaceutical: Earnings Trends and Recent Developments
Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.
A Post-2Q17 Update on Pfizer’s Oncology Drugs: Sutent, Xalkori, and Inlyta
In 2Q17, Inlyta generated revenues of ~$88 million, which represents an ~19% decline on a YoY basis and ~4% growth on a quarter-over-quarter basis.
How Merck’s Oncology Drugs Emend and Temodar Could Perform in 2017
In 2016, Merck’s (MRK) Emend reported revenues of around $549 million, which reflected 3% year-over-year growth.
Novartis Receives 2 Breakthrough Therapy Designations in January
In January 2018, the FDA granted a BTD to Novartis’s (NVS) Promacta for use along with standard immunosuppressive therapy.
Revlimid Could Continue to Drive Celgene’s Revenue Growth in 2017
In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.
Humira May Continue to Drive AbbVie’s Revenue Growth
In 2016, AbbVie’s (ABBV) drug Humira reported revenue of ~$16.0 billion, which reflected a ~15% year-over-year (or YoY) rise.
Januvia and Janument: An Update on Merck’s Diabetes Franchise after 2Q17
In 2Q17, Merck’s (MRK) Januvia generated revenues of around $948 million, which reflected an ~11% decline on a year-over-year basis and 13% growth on a quarter-over-quarter basis.
How Merck’s Zepatier and Isentress Are Positioned after 2Q17
In 2Q17, Merck’s (MRK) Zepatier generated revenues of ~$517 million compared to $112 million in 2Q16.
What Else Could Drive Gilead’s Long-Term Growth?
In December 2017, Kite, a Gilead Sciences (GILD) company, presented long-term follow-up data from its pivotal ZUMA-1 trial of Yescarta.
A Look into Merck’s Immunology and Oncology Portfolio
In 1H17, Remicade generated revenues of around $437 million, which is a 37% decline year-over-year.
Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17
In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.
How Amgen’s Nephrology Drugs Are Positioned after 2Q17?
In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.
Eylea Could Continue to Generate High Revenue
Regeneron Pharmaceuticals (REGN) markets Eylea in the United States, and Bayer (BAYZF) commercializes the drug outside the US market.
The Latest on TEVA’s Oncology Business
In 1H17, Teva Pharmaceutical’s (TEVA) oncology business generated revenues of ~$550 million, or ~9% lower YoY (year-over-year).
Understanding the Performance of Merck’s Hospital Acute Care Drugs Noxafil and Cubicin
In 4Q17, Merck’s (MRK) Cubicin reported revenues of $92 million, which was ~23% lower on a YoY (year-over-year) basis.
How’s Celgene’s Abraxane Positioned after 4Q17?
In 4Q17, Celgene’s (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis.
A Financial Overview of Bausch Health in October
Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.
A Look at Spectrum’s Financial Position in September
In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017.
FDA Approves Zimmer Biomet’s ROSA, Stock Up 2.6%
Today, Zimmer Biomet Holdings’ (ZBH) ROSA Knee System received FDA 510(k) clearance for robotically assisted total knee replacement surgeries.
Sarepta Therapeutics Stock Rose 96% in 2018
On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its prior close.
Pfizer and GlaxoSmithKline Form a Joint Venture
On December 19, GlaxoSmithKline (GSK) and Pfizer (PFE) entered into an agreement to combine both of their consumer health businesses.
How Did Medtronic’s Restorative Therapies Group Perform?
Medtronic’s (MDT) Spine Therapies generated revenues of $1.3 billion in the first half of fiscal 2019.
How Medtronic’s Minimally Invasive Therapies Group Has Performed
Medtronic’s MITG segment generated revenues of $4.1 billion in the first half of fiscal 2019 compared to $4.4 billion in the first half of fiscal 2018.
How Does Medtronic’s Restorative Therapies & Diabetes Group Look?
Medtronic’s Restorative Therapies Group consists of Spine, Brain, Specialty and Pain therapies.
Merck’s Stock Price Has Increased ~34% in 2018
On November 16, Merck’s stock price closed at $76.06, which represents ~1.63% growth from its close of $74.84 on November 15.
Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?
Jazz Pharmaceuticals’ Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017.
A Look at Merck’s Diabetes and Women’s Health Business
Merck & Co.’s (MRK) Januvia generated revenues of $927 million in the third quarter, reflecting an ~8% YoY (year-over-year) decline.
A Performance Overview of Merck’s Hospital Acute Care Business
Merck & Co.’s (MRK) Bridion generated revenues of $217 million in the third quarter, which reflected a ~17% YoY growth.
How Wall Street Analysts View Merck
On October 25, Merck (MRK) announced a dividend of $0.55 per share for its outstanding common stock in the fourth quarter of 2018.
How JNJ’s Invega Sustenna and Risperdal Consta Performed
Johnson & Johnson’s (JNJ) Invega Sustenna, Xeplion, Trinza, and Trevicta combined witnessed solid growth in the third quarter.
A Look into Johnson & Johnson’s Diabetes Care Business
In the US and international markets, Johnson & Johnson’s Diabetes Care segment generated third-quarter net revenues of $125.0 million and $190.0 million, respectively.
An Overview of Johnson & Johnson’s Neuroscience Segment
Of the 20 analysts tracking Johnson & Johnson stock in October, four recommended a “strong buy” while six analysts recommended a “buy.”
Delstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio
Gilead Sciences’ Atripla, Genvoya, and Stribild generated revenues of $663.0 million, $2.2 billion, and $361.0 million, respectively, in the first half of 2018.
Why Invitae Stock Rose 23% in Week Ended August 24
On August 24, Invitae (NVTA) stock closed at $12.56, which represents a ~4.75% growth from its prior day’s close of $11.99.
Risdiplam: Could It Be PTC Therapeutics’ Future Growth Driver?
In June, PTC Therapeutics (PTCT) presented its updated interim clinical data from the Phase 1 FIREFISH trial.
How Amgen’s Nplate, Vectibix, and Neupogen Performed in 1Q18
In 1Q18, Amgen’s (AMGN) Nplate revenue grew 16% YoY (year-over-year) to $179 million from $154 million, primarily driven by unit demand.
How Celgene Performed in 1Q18
In 1Q18, Celgene’s (CELG) revenue grew 20% year-over-year to $3.5 billion from $3.0 billion, boosted by Revlimid, Pomalyst, and Otezla sales.
Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018
In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY growth in local currencies.
Cabometyx Could Be Exelixis’s Long-Term Growth Driver
In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx.
How Did Novartis’s Established Medicines Segment Perform in 2017?
In 4Q17, Novartis’s (NVS) Galvus generated revenues of $327 million, which is ~10% growth on a year-over-year (or YoY) basis and 5% growth quarter-over-quarter.
How Is Novartis’s Xolair Positioned after 4Q17?
In 4Q17, Novartis’s (NVS) Xolair generated revenues of $247 million, which reflected ~14% growth on a year-over-year (or YoY) basis and ~1% growth on a quarter-over-quarter basis.
A Look at Novartis’s Immunology and Dermatology Segment’s Performance
In 4Q17, Novartis’s Immunology and Dermatology segment generated revenues of $1.2 billion, ~30% growth on a year-over-year (or YoY) basis and ~9% growth quarter-over-quarter.
Eli Lilly’s Jardiance, Trajenta, and Trulicity in 2017
In 4Q17, Eli Lilly’s (LLY) Jardiance generated revenues of $143.2 million compared to $76.1 million in 4Q16.
Behind the Performance of AZN’s Daliresp, Tudorza, and Duaklir
In 4Q17, AstraZeneca’s (AZN) Daliresp reported revenues of $53.0 million, which reflected ~29.0% year-over-year (or YoY) growth.
The Performance of AstraZeneca’s Symbicort and Pulmicort in 2017
In 4Q17, AstraZeneca’s (AZN) Symbicort generated revenues of $752.0 million, which is ~2.0% growth on a year-over-year basis.
AstraZeneca’s Tagrisso Witnessed Solid Growth in 2017
In 4Q17, AstraZeneca’s (AZN) Tagrisso reported revenues of $304.0 million compared to $147.0 million in 4Q16.
Inside Pfizer’s Rare Disease Segment Performance in 2017
In 4Q17, Pfizer’s BeneFix reported revenues of $150 million, which represents a ~11% decline YoY and a ~1% decline quarter-over-quarter.
How Pfizer’s Peri-LOE Products Performed in 2017
Pfizer’s (PFE) Peri-LOE products refer to those products that lost patient protection recently or are expected to lose patient protection soon.
Inside Pfizer’s Vaccines Performance in 4Q17 and 2017
In 4Q17, Pfizer (PFE) generated revenues of $1.6 billion from the sale of vaccines, which reflected a ~8% rise on a YoY (year-over-year) basis.
Pfizer’s Bosulif Had a Strong Performance in 4Q17 and 2017
In 4Q17, Pfizer’s (PFE) Bosulif generated revenues of $70 million, which reflected ~52% growth on a YoY (year-over-year) basis.